Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $10.70, but opened at $12.43. Gyre Therapeutics shares last traded at $11.29, with a volume of 85,274 shares trading hands.
Analysts Set New Price Targets
Separately, Noble Financial started coverage on Gyre Therapeutics in a report on Tuesday. They issued an "outperform" rating for the company.
Check Out Our Latest Research Report on GYRE
Gyre Therapeutics Stock Performance
The stock's 50 day moving average price is $11.25 and its 200-day moving average price is $12.33.
Insider Buying and Selling at Gyre Therapeutics
In related news, President Songjiang Ma sold 2,000 shares of the business's stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders sold 34,054 shares of company stock valued at $383,057. 19.52% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Gyre Therapeutics
Several institutional investors have recently bought and sold shares of GYRE. SBI Securities Co. Ltd. purchased a new stake in shares of Gyre Therapeutics during the 4th quarter valued at $1,225,000. Charles Schwab Investment Management Inc. increased its position in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock valued at $1,425,000 after buying an additional 90,557 shares in the last quarter. Geode Capital Management LLC raised its stake in Gyre Therapeutics by 16.9% in the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock valued at $3,808,000 after buying an additional 43,840 shares during the last quarter. Advantage Alpha Capital Partners LP acquired a new stake in Gyre Therapeutics in the third quarter worth about $334,000. Finally, Northern Trust Corp grew its stake in shares of Gyre Therapeutics by 9.1% during the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock worth $1,251,000 after acquiring an additional 8,624 shares during the last quarter. 23.99% of the stock is currently owned by institutional investors and hedge funds.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Articles
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
